Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/97106
Citations | ||
Scopus | Web of ScienceĀ® | Altmetric |
---|---|---|
?
|
?
|
Type: | Journal article |
Title: | Expression of androgen receptor splice variants in clinical breast cancers |
Author: | Hickey, T. Irvine, C. Dvinge, H. Tarulli, G. Hanson, A. Ryan, N. Pickering, M. Birrell, S. Hu, D. Mackenzie, P. Russell, R. Caldas, C. Raj, G. Dehm, S. Plymate, S. Bradley, R. Tilley, W. Selth, L. |
Citation: | Oncotarget, 2015; 6(42):44728-44744 |
Publisher: | Impact Journals |
Issue Date: | 2015 |
ISSN: | 1949-2553 1949-2553 |
Statement of Responsibility: | Theresa E. Hickey, Connie M. Irvine, Heidi Dvinge, Gerard A. Tarulli, Adrienne R. Hanson, Natalie K. Ryan, Marie A. Pickering, Stephen N. Birrell, Dong Gui Hu, Peter I. Mackenzie, Roslin Russell, Carlos Caldas, Ganesh V. Raj, Scott M. Dehm, Stephen R. Plymate, Robert K. Bradley, Wayne D. Tilley, Luke A. Selth |
Abstract: | The importance of androgen receptor (AR) signaling is increasingly being recognized in breast cancer, which has elicited clinical trials aimed at assessing the efficacy of androgen deprivation therapy (ADT) for metastatic disease. In prostate cancer, resistance to ADT is frequently associated with the emergence of androgen-independent splice variants of the AR (AR variants, AR-Vs) that lack the LBD and are constitutively active. Women with breast cancer may be prone to a similar phenomenon. Herein, we show that in addition to the prototypical transcript, the <i>AR</i> gene produces a diverse range of AR-V transcripts in primary breast tumors. The most frequently and highly expressed variant was AR-V7 (exons 1/2/3/CE3), which was detectable at the mRNA level in > 50% of all breast cancers and at the protein level in a subset of ERα-negative tumors. Functionally, AR-V7 is a constitutively active and ADT-resistant transcription factor that promotes growth and regulates a transcriptional program distinct from AR in ERα-negative breast cancer cells. Importantly, we provide <i>ex vivo</i> evidence that AR-V7 is upregulated by the AR antagonist enzalutamide in primary breast tumors. These findings have implications for treatment response in the ongoing clinical trials of ADT in breast cancer. |
Keywords: | androgen receptor; breast cancer; androgen deprivation therapy; alternative splicing; biomarker |
Description: | Published: November 05, 2015 |
Rights: | Creative Commons License. All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License. PII: 6296 |
DOI: | 10.18632/oncotarget.6296 |
Published version: | http://dx.doi.org/10.18632/oncotarget.6296 |
Appears in Collections: | Aurora harvest 3 Medicine publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
hdl_97106.pdf | Published version | 5.33 MB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.